Fundraising FoxJnana Therapeutics
acquired by OtsukaAustin, US · 7 known investors
Find your way into Jnana Therapeutics
Sign up to find every way you can get introduced to Jnana Therapeutics
- Your email: who you already know at Jnana Therapeutics, and who your contacts know
- 2nd- and 3rd-degree connections: people you know who worked, studied or invested with the Jnana Therapeutics team
- Your LinkedIn: the connections who can make the intro for you
We rank every route by how warm it is, so you raise on warm intros instead of cold emails.
Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.
Investors · 7
How we know: Avalon BioVentures's portfolio page · board seat on SEC Form D · open dataset · 5k.vc investor directory · Not right? Tell us
How we know: Bain Capital Life Sciences's portfolio page · jnanatx.com · Not right? Tell us
How we know: Pfizer Venture Investments's portfolio page · Not right? Tell us
How we know: RA Capital's portfolio page · jnanatx.com · Not right? Tell us
How we know: jnanatx.com · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · Not right? Tell us
How we know: a partner's Signal profile · board seat on SEC Form D · jnanatx.com · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountSeries CNov 2022
Bain Capital Life Sciences (lead), Avalon Ventures, Pfizer Ventures, Polaris Partners, RA Capital Management, Versant Ventures
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Frequently asked questions
- What does Jnana Therapeutics do?
- Jnana has developed RAPID, a next-generation chemoproteomics platform that enables rapid discovery of small molecule drugs targeting previously inaccessible disease targets by identifying novel binding sites on complex proteins. The platform uses proprietary reactive affinity probes and high-throughput screening to accelerate drug discovery across challenging target classes including transporters, transcription factors, and GPCRs.
- Who are Jnana Therapeutics's investors?
- Jnana Therapeutics's investors include Avalon BioVentures, Bain Capital Life Sciences, Pfizer Venture Investments, RA Capital, Pfizer Ventures, Polaris Partners, Versant Ventures.
- Who acquired Jnana Therapeutics?
- Jnana Therapeutics was acquired by Otsuka.
- Where is Jnana Therapeutics headquartered?
- Jnana Therapeutics is headquartered in Austin, US.